ASA EC TABLET (DELAYED-RELEASE)

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

ACETYLSALICYLIC ACID

Prieinama:

SANIS HEALTH INC

ATC kodas:

B01AC06

INN (Tarptautinis Pavadinimas):

ACETYLSALICYLIC ACID

Dozė:

81MG

Vaisto forma:

TABLET (DELAYED-RELEASE)

Sudėtis:

ACETYLSALICYLIC ACID 81MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

1000

Recepto tipas:

OTC

Gydymo sritis:

SALICYLATES

Produkto santrauka:

Active ingredient group (AIG) number: 0101169013; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2014-07-24

Prekės savybės

PRODUCT MONOGRAPH
ASA EC
Acetylsalicylic
Acid Delayed-release Tablets USP
81 mg
Analgesic, anti-inflammatory,
antipyretic and
Platelet aggregation inhibitor
SANIS HEALTH INC.
1 President’s Choice Circle
Brampton, Ontario
L6Y 5S5
DATE OF REVISION:
July 26, 2022
www.sanis.com
SUBMISSION CONTROL NUMBER: 265899
Page 2 of 40
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................4
WARNINGS AND PRECAUTIONS
.............................................................................4
ADVERSE
REACTIONS..............................................................................................7
DRUG INTERACTIONS
..............................................................................................7
DOSAGE AND ADMINISTRATION
.........................................................................
10
OVERDOSAGE
.........................................................................................................
11
ACTION AND CLINICAL
PHARMACOLOGY.........................................................
12
STORAGE AND STABILITY
....................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
................................................................... 13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 14
PART II : SCIENTIFIC INFORMATION
.........................................................................
15
PHARMACEUTICAL INFORMATION
.....................................................................
15
CLINICAL TRIALS
...................................................................................................
16
DETAILED
PHARMACOLOGY..